CL2023002879A1 - Emulsiones para anestésicos locales - Google Patents

Emulsiones para anestésicos locales

Info

Publication number
CL2023002879A1
CL2023002879A1 CL2023002879A CL2023002879A CL2023002879A1 CL 2023002879 A1 CL2023002879 A1 CL 2023002879A1 CL 2023002879 A CL2023002879 A CL 2023002879A CL 2023002879 A CL2023002879 A CL 2023002879A CL 2023002879 A1 CL2023002879 A1 CL 2023002879A1
Authority
CL
Chile
Prior art keywords
emulsion
local anesthetic
emulsions
local anesthetics
oil
Prior art date
Application number
CL2023002879A
Other languages
English (en)
Inventor
Andrew Xian Chen
Lijia Chen
Damian Mcloud
Original Assignee
Cali Biosciences Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cali Biosciences Us Llc filed Critical Cali Biosciences Us Llc
Publication of CL2023002879A1 publication Critical patent/CL2023002879A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una emulsión y el uso de una emulsión para el alivio del dolor que comprende un anestésico local, lecitina, aceite y una fase acuosa, en donde el anestésico local no es covalente unido a las gotas de aceite de la emulsión y la emulsión es física y químicamente estable y la emulsión proporciona una mejor seguridad, farmacocinética de liberación prolongada y una duración prolongada de la acción del anestésico local.
CL2023002879A 2021-03-31 2023-09-27 Emulsiones para anestésicos locales CL2023002879A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163169121P 2021-03-31 2021-03-31
US17/369,369 US11992483B2 (en) 2021-03-31 2021-07-07 Emulsions for local anesthetics

Publications (1)

Publication Number Publication Date
CL2023002879A1 true CL2023002879A1 (es) 2024-02-09

Family

ID=83450711

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002879A CL2023002879A1 (es) 2021-03-31 2023-09-27 Emulsiones para anestésicos locales

Country Status (12)

Country Link
US (1) US11992483B2 (es)
EP (1) EP4313018A1 (es)
JP (1) JP2024512704A (es)
KR (1) KR20230163543A (es)
CN (1) CN117412743A (es)
AU (1) AU2022249201A1 (es)
BR (1) BR112023019572A2 (es)
CA (1) CA3212259A1 (es)
CL (1) CL2023002879A1 (es)
CO (1) CO2023012680A2 (es)
MX (1) MX2023011487A (es)
WO (1) WO2022212166A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11992483B2 (en) 2021-03-31 2024-05-28 Cali Biosciences Us, Llc Emulsions for local anesthetics

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5693337A (en) 1994-07-13 1997-12-02 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion
BR9907832A (pt) 1998-02-10 2000-10-31 Sicor Inc Composição de propofol contendo sulfito
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
DE69940735D1 (de) 1998-07-17 2009-05-28 Pacira Pharmaceuticals Inc Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen
US7261903B1 (en) 1999-02-22 2007-08-28 Guy Weinberg Lipid emulsions in the treatment of systemic poisoning
US6100302A (en) 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics
US7476400B2 (en) 2001-11-13 2009-01-13 Ferndale Ip, Inc. High-concentration lidocaine compositions and methods for their preparation
WO2003105817A1 (en) 2002-05-02 2003-12-24 Fdl, Inc. Novel parenteral composition comprising propofol
US20060233721A1 (en) 2002-10-25 2006-10-19 Foamix Ltd. Foam containing unique oil globules
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8476010B2 (en) 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US7713440B2 (en) 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
US20090192230A1 (en) 2004-01-14 2009-07-30 Koichi Takeda Propofol-containing fat emulsion preparation
US20050196416A1 (en) 2004-02-05 2005-09-08 Kipp James E. Dispersions prepared by use of self-stabilizing agents
JP2008502690A (ja) 2004-06-15 2008-01-31 アンドリュー シァン チェン， リン脂質組成物ならびにその調製方法および使用方法
WO2007000662A2 (en) 2005-02-03 2007-01-04 Taro Pharmaceuticals U.S.A., Inc. Novel propofol composition comprising ascorbic acid or pharmaceutically acceptable salts thereof
WO2006112276A1 (ja) 2005-04-13 2006-10-26 Otsuka Pharmaceutical Factory, Inc. プロポフォール含有脂肪乳剤
US20090131538A1 (en) 2005-05-27 2009-05-21 Taro Pharmaceuticals North America, Inc. c/o Taro Pharmaceuticals U.S.A., Inc. Novel propofol composition comprising a pharmaceutically acceptable salt of formaldehyde sulfoxylate
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
MX2008013339A (es) 2006-04-20 2009-01-26 Amgen Inc Formulaciones de emulsion estable.
EP2034961A1 (de) 2006-06-30 2009-03-18 Gertrud Langhoff Solubilisatformulierungen
DE102008034944B4 (de) 2008-07-26 2017-03-16 Arivine Pharma Ag Mikroemulsion
US8119694B2 (en) 2008-08-15 2012-02-21 Arcion Therapeutics, Inc. High concentration local anesthetic formulations
US20100105125A1 (en) 2008-10-24 2010-04-29 Bioprocessh20 Llc Systems, apparatuses and methods for cultivating microorganisms and mitigation of gases
US9132090B2 (en) 2009-01-13 2015-09-15 Chetan Majmudar Propofol based anesthetic with preservative
CN101904814A (zh) 2009-06-04 2010-12-08 上海恒瑞医药有限公司 制备载药乳剂的方法
WO2011075623A1 (en) 2009-12-18 2011-06-23 Latitude Pharmaceuticals, Inc. One - phase gel compos ition compri s ing phos pholi pids
CN102370619A (zh) * 2010-08-18 2012-03-14 罗和国 脂肪乳乳化局麻药
ES2618907T3 (es) 2010-12-03 2017-06-22 Allergan, Inc. Composiciones farmacéuticas en crema que comprenden oximetazolina
CN102526753B (zh) 2011-12-15 2014-01-22 成都师创生物医药科技有限公司 一种以磷脂为基质的原位相变凝胶缓释系统及其制备方法
US9668974B2 (en) 2012-05-10 2017-06-06 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
CN105451710A (zh) 2013-03-22 2016-03-30 利普泰股份公司 用于治疗和/或护理皮肤、粘膜和/或指甲的外泌多糖
US10426727B2 (en) 2014-04-25 2019-10-01 Wisconsin Alumni Research Foundation Fluoropolymer emulsions with branched semifluorinated block copolymer or phospholipid surfactant for the delivery of hydrophobic drugs
MX2017002896A (es) 2014-09-04 2017-05-30 Sichuan Haisco Pharmaceutical Co Ltd Uso del agente de refuerzo del receptor del acido gamma-aminobutirico tipo a (gabaa) en la preparacion de un sedante y medicamento anestesico.
US10894150B2 (en) * 2015-04-23 2021-01-19 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
CN107708670A (zh) 2015-06-01 2018-02-16 奥托泰利克有限责任公司 磷脂包衣的治疗剂纳米颗粒和有关的方法
US20160346221A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
EP3346998A4 (en) 2015-08-17 2019-08-28 Sidmak Laboratories (India) PVT. Ltd. TOPIC FILM DELIVERY SYSTEM
WO2017037663A1 (en) 2015-09-02 2017-03-09 Cadila Healthcare Limited Topical compositions comprising corticosteroids
BR112018068938B1 (pt) 2016-03-18 2022-05-17 International Flavors & Fragrances Inc Microcápsula
WO2017218630A2 (en) 2016-06-15 2017-12-21 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
WO2018013595A1 (en) 2016-07-11 2018-01-18 Theracell, Inc. Bone derived fibers and oxygenated wound treatments
CN109010261B (zh) 2017-06-22 2020-11-06 四川大学 一种小分子药物原位相变凝胶缓释系统及其制备方法
CN111840553A (zh) 2019-04-15 2020-10-30 湖州依诺唯新药物制剂有限公司 脂性药物制剂及其应用
EP4034087A4 (en) 2019-09-23 2023-10-25 DDS Research Inc. LIPID VESICLE COMPOSITIONS CONTAINING PENETRATION PROMOTING AGENTS
CN113018248B (zh) 2019-12-23 2022-07-22 南京清普生物科技有限公司 一种缓释递药系统
WO2021143745A1 (zh) 2020-01-14 2021-07-22 中国科学院上海药物研究所 一种长效罗哌卡因药物组合物及其制备方法和用途
EP4157998A1 (en) 2020-06-02 2023-04-05 The Johns Hopkins University Gel for use in gastrointestinal endoscopy and endodermal, epidermal, and other mucosal uses
JP2023546297A (ja) 2020-10-16 2023-11-01 バイオスーペリア テクノロジー，インコーポレイテッド 肺治療組成物
CN114762676B (zh) 2021-01-14 2024-03-08 南京清普生物科技有限公司 一种缓释制剂组合物
CA3209512A1 (en) 2021-02-23 2022-09-01 Edison Oncology Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases
WO2022186802A1 (en) 2021-03-01 2022-09-09 Sabanci Ahmet Uemit Liposomal ozone nanosolutions
BR112023018833A2 (pt) 2021-03-16 2023-12-26 Eli?Ka Ma?Kova Composições de filme oromucosal compreendendo partículas de epinefrina
WO2022207580A2 (en) 2021-03-27 2022-10-06 TRx Biosciences Limited Compositions having improved bioavailability of therapeutics
US11992483B2 (en) 2021-03-31 2024-05-28 Cali Biosciences Us, Llc Emulsions for local anesthetics
WO2022217147A1 (en) 2021-04-09 2022-10-13 Rosenfeld Mark J Methods for improving cutaneous permeation of cannabinoids and fatty acid amides

Also Published As

Publication number Publication date
AU2022249201A1 (en) 2023-09-21
US20220313669A1 (en) 2022-10-06
EP4313018A1 (en) 2024-02-07
JP2024512704A (ja) 2024-03-19
KR20230163543A (ko) 2023-11-30
MX2023011487A (es) 2023-10-04
US11992483B2 (en) 2024-05-28
BR112023019572A2 (pt) 2023-11-14
WO2022212166A1 (en) 2022-10-06
CO2023012680A2 (es) 2023-11-20
CN117412743A (zh) 2024-01-16
CA3212259A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
CL2023002879A1 (es) Emulsiones para anestésicos locales
CY1124225T1 (el) Ακροφυσιο ρινικου εκνεφωματος για χρηση σε ιατρικη συριγγα
CO2022002685A2 (es) Nanopartículas lipídicas mejoradas para el suministro de ácidos nucleicos
SG11201901742QA (en) Oil-in-water type emulsion having excellent stability and cosmetic composition comprising same
BR112016028961A8 (pt) fibras eletrotorcidas, seu método de preparação e seu uso, bem como composição, e kit
BR112014017920A8 (pt) Preparação cosmética e/ou dermatológica à base de uma emulsão de água em óleo e uso da combinação de dois emulsificantes de água/óleo
UY36682A (es) Composicion farmacéutica tópica de un derivado de estilbeno
AR079412A1 (es) Emulsiones estables de aceite en agua
CO6270209A2 (es) Un beta bloqueante para el tratamiento de los hemangiomas
AR098076A1 (es) Dispositivo de inyección
BRPI0704238A (pt) preventivo da doença de coccidiose e clostrìdica e/ou terapia para a doença de coccidiose e clostridica
BRPI0514335B8 (pt) conjunto de seringa e agulha retrátil
MX2014015657A (es) Composicion topica que comprende un polimero formador de pelicula para liberar un ingrediente activo a la piel.
CL2022002606A1 (es) Implante ocular que contiene un inhibidor de la tirosina cinasa
BR112014005595A2 (pt) preparação aquosa cosmética ou dermatológica para aplicação em pele molhada ou úmida, método para cuidar da pele e método de barbear em úmido
CL2021000509A1 (es) Composiciones farmacéuticas semisólidas de base oleosa conteniendo pirfenidona para su aplicación en la reparación tisular
ES2036587T3 (es) Medicamentos para el tratamiento o prevencion del sindrome de abstinencia.
BR112023020308A2 (pt) Acessórios compressíveis com zonas comportamentais diferentes
BRPI0516749B8 (pt) composições compreendendo antagonistas dos receptores 5-ht2a e 5-ht6 e uso destes para o tratamento de distúrbios cognitivos
BR112013020309A2 (pt) dispersões agroquímicas oleosas estáveis
KR960700041A (ko) 신규한 경피 흡수제제(Novel percutaneously absorbable preparation)
BRPI0403269A (pt) emulsão múltipla
BR112015020058A2 (pt) dispositivo de distribuição e processo cosmético
BR112015020066A8 (pt) composição na forma de uma emulsão óleo-em-água, processo cosmético para tratar e/ou cuidar das matérias queratínicas humanas, processo cosmético para tratar a transpiração humana, dispositivo de distribuição e uso de uma composição
CL2020001272A1 (es) Emulsiones para el tratamiento de infecciones de mucosas.